Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial

This publication has 37 references indexed in Scilit:

• Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study
  Published by Elsevier ,2008
• Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002
  Journal of Clinical Oncology, 2007
• A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study
  Gynecologic Oncology, 2007
• Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel
  Investigational New Drugs, 2007
• Docetaxel and gemcitabine combination in 133 advanced soft‐tissue sarcomas: A retrospective analysis
  International Journal of Cancer, 2006
• Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study
  Journal of Clinical Oncology, 2005
• Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study
  Gynecologic Oncology, 2004
• Trimetrexate in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus: A Phase II Study of the Gynecologic Oncology Group
  Gynecologic Oncology, 2002
• Prolonged Oral Etoposide in Recurrent or Advanced Leiomyosarcoma of the Uterus: A Gynecologic Oncology Group Study
  Gynecologic Oncology, 1998
• Phase II Trial of Etoposide in Leiomyosarcoma of the Uterus: A Gynecologic Oncology Group Study
  Gynecologic Oncology, 1996